DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia (AML)

Leukemia. 1992:6 Suppl 2:89-91.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Amsacrine / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / administration & dosage
  • DNA / therapeutic use*
  • DNA Adducts*
  • Daunorubicin / administration & dosage
  • Doxorubicin / therapeutic use*
  • Drug Administration Schedule
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / mortality
  • Mercaptopurine / administration & dosage
  • Methotrexate / administration & dosage
  • Middle Aged
  • Prednisolone / administration & dosage
  • Prednisone / administration & dosage
  • Survival Analysis
  • Thioguanine / administration & dosage
  • Vincristine / administration & dosage

Substances

  • DNA Adducts
  • doxorubicin-DNA
  • Amsacrine
  • Cytarabine
  • Vincristine
  • Doxorubicin
  • DNA
  • Prednisolone
  • Mercaptopurine
  • Thioguanine
  • Prednisone
  • Methotrexate
  • Daunorubicin

Supplementary concepts

  • POMP protocol